Label: PHENAZOPYRIDINE HYDROCHLORIDE 200 MG- phenazopyridine hydrochloride tablet

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated December 21, 2021

If you are a consumer or patient please visit this version.

  • INDICATIONS AND USAGE

    Phenazopyridine is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of
    Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when
    symptoms are controlled. The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible
    with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed two days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after two days. (See DOSAGE AND ADMINISTRATION section.)

  • DOSAGE AND ADMINISTRATION

    200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.

    When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.

  • INACTIVE INGREDIENTS

    Phenazopyridine HCl Tablets, USP contains the following
    inactive ingredients: croscarmellose sodium, colloidal silicon
    dioxide, hydroxypropyl methyl cellulose, magnesium stearate,
    maize (corn starch) microcrystalline cellulose, polyethylene
    glycol, povidone and pregelatinized starch.

  • PRINCIPAL DISPLAY PANEL

    01b LBL_Phenazopyridine HCl 200mg_100 ct_front

    01b LBL_Phenazopyridine HCl 100mg_insert_Page_1

    01b LBL_Phenazopyridine HCl 100mg_insert_Page_2

    01b LBL_Phenazopyridine HCl 100mg_insert_Page_3

    01b LBL_Phenazopyridine HCl 100mg_insert_Page_401b LBL_Phenazopyridine HCl 100mg_insert_Page_5

  • INGREDIENTS AND APPEARANCE
    PHENAZOPYRIDINE HYDROCHLORIDE   200 MG
    phenazopyridine hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:70795-1252
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHENAZOPYRIDINE HYDROCHLORIDE (UNII: 0EWG668W17) (PHENAZOPYRIDINE - UNII:K2J09EMJ52) PHENAZOPYRIDINE HYDROCHLORIDE200 mg
    Inactive Ingredients
    Ingredient NameStrength
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)  
    POVIDONE (UNII: FZ989GH94E)  
    Product Characteristics
    ColorbrownScoreno score
    ShapeROUNDSize10mm
    FlavorImprint Code G17
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:70795-1252-0100 in 1 BOTTLE; Type 0: Not a Combination Product12/12/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other12/12/2020
    Labeler - GRAXCELL PHARMACEUTICAL, LLC (056556923)